CDC's Advisory Committee Backs Pneumococcal Vaccine From Pfizer, Merck

• The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer Inc's (NYSE: PFE) Prevnar 20 pneumococcal vaccine for routine use.

• The CDC's Advisory Committee has also voted to recommend vaccination either with a sequential regimen of Merck & Co Inc's (NYSE: PFE) Vaxneuvance followed by Pneumovax 23 or with a single dose 20-valent pneumococcal conjugate vaccine.

• These updates would apply to adults 65 years or older and adults with certain underlying medical conditions who have not previously received a pneumococcal conjugate vaccine or whose previous pneumococcal vaccination history is unknown.

• Related Link: Merck's Pneumococcal Vaccine Lands FDA Nod, Just a Few Weeks After Its Rival.

• Price Action: PFE shares are up 0.70% at $43.10, MRK shares are up 0.12% at $81.17 during the premarket session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines

• Merck Recalls One Lot Of Cubicin Antibiotic Over Glass Particles Presence In Vials

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.